<DOC>
	<DOCNO>NCT03006796</DOCNO>
	<brief_summary>This observational prospective study azilsartan medoxomil / chlorthalidone compare irbesartan / hydrochlorothiazide routine therapy patient arterial hypertension obesity .</brief_summary>
	<brief_title>Observational Study Azilsartan/Chlorthalidone Irbesartan/Hydrochlorothiazide Hypertension Obesity .</brief_title>
	<detailed_description>Observational Prospective stUdy aZilsartan medoxomil/ chlorthalidone compare irbesartan/hydrochlorothiaZide combination therapy patient arteriaL hypertension obEsity routine clinical practice ( PUZZLE ) . The study population 94 patient untreated poorly control arterial hypertension obesity . The main inclusion criterion : 1 . Male female 35-55 year old . 2 . Diagnosis essential arterial hypertension I-II grade . 3 . Patients obesity ( BMI ≥ 30 kg/m² ) 4 . Patients untreated arterial hypertension ( clinic SBP ≥ 140 mmHg , DBP ≥ 90 mmHg previous antihypertensive treatment . 5 . Patients poorly control arterial hypertension ( clinic SBP ≥ 140 mmHg , DBP ≥ 90 mmHg previous antihypertensive treatment . 6 . Written informed consent . The main exclusion criterion : 1 . Patients symptomatic organ damage ( myocardial infarction , stroke , angina pectoris , chronic kidney disease ≥ 4 grade , diabetes ) . 2 . Patients secondary arterial hypertension . 3 . Patients intolerance angiotensin II receptor blocker , thiazide diuretic . 4 . Patients contraindication study drug accordance Russian instruction . 5 . Patients currently enrol clinical trial . The treatment period 6 month . The study plan include 4 basic 1 additional visit plan : initial visit , 3 follow-up ( include additional ) study-end visit .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1. male female 3555 year old , 2. diagnosis III grade essential AH , 3. patient obesity ( BMI ≥ 30 kg/m² ) , 4. patient untreated AH ( office SBP ≥ 140 mmHg , DBP ≥ 90 mmHg , previous antihypertensive therapy ) , 5. patient poorly control AH ( office SBP ≥ 140 mmHg , DBP ≥ 90 mmHg previous antihypertensive therapy ) , 6. write informed consent form ( ICF ) . 1. patient symptomatic organ damage ( myocardial infarction , stroke , angina pectoris , chronic kidney disease stage ≥ 4 , diabetes ) , 2. patient intolerance ARB , thiazide diuretic , 3. secondary AH , 4. patient contraindication study drug accordance Russian instruction , 5. patient currently enrol clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obesity</keyword>
</DOC>